Secukinumab

Secukinumab for rheumatology: development and its potential place in therapy

Secukinumab for rheumatology: development and its potential place in therapy Marije I Koenders, Wim B…
dovepress.com|By Dove Press

The Th17 pathway is somewhat of a Jekyll & Hyde thing, playing either a protective/reparative role or a destructive/pathological role.  Its main protective role is against fungus.

IL6 and TGF-beta drive a housekeeping differentiation, while IL21, IL23 and IL1-beta induce a pro-inflammatory differentiation.  IFN-gamma (Th1) and IL4 (Th2) inhibit Th17 differentiation altogether.

The main Th17 effector cytokines are IL17A, IL17F, IL21 and IL22. The latter in turn characterises a whole distinct subset of T-helper population called Th22. But that’s another story for another day.


Secukinumab for psoriasis at 4 years: undiminished efficacy and safety

Image result for psoriasis

VIENNA – Secukinumab showed reassuring safety with no drop-off in efficacy for psoriasis after 4 years of treatment.
mdedge.com

PsA Patients Experience Sustained Improvement with Secukinumab

PsA patients show sustained improvement at two years with secukinumab, clinical trial shows.
rheumatologynetwork.com

Secukinumab Provides Sustained Improvements in AS

©SutthaBurawonk/Shutterstock.com
EULAR 2016: Secukinumab prevents radiographic progression in 80 percent of ankylosing spondylitis…
rheumatologynetwork.com